Susanna Fletcher Greer, Chief Scientific Officer of the V Foundation, shared a post on LinkedIn by Jun Qi, Associate Professor Of Medicine at Dana-Farber Cancer Institute, adding:
“Congratulations Jun Qi – beautiful work! And thank you for recognizing the V Foundation support.
LinkedIn friends: this research identifies a promising new way to target one of the deadliest childhood brain cancers, using a treatment designed to reach the brain and slow tumor growth in preclinical models… research allowing desperately needed hope for more effective therapies for children and families facing diffuse midline glioma.”
Quoting Jun Qi’s post:
“Excited to share that our collaborative work with Mariella Filbin and her wonderful team is now online in Neuro-Oncology Society for Neuro-Oncology. We validated HDAC2 as an important and tractable target for H3K27M DMG in both cellular and animal models.
Thank you for wonderful collaboration Mariella Filbin and Filbin lab. Thanks for the support from Berkley Gryder. Congratulations to everyone from Qi lab and Filbin lab who contributed to this study, particularly, Andrew Groves and Orville Kirkland. I am always thankful for the chance to learn and work together.
Thanks for all the support from all these pediatric cancer foundations, including Alex’s Lemonade Stand Foundation, Curing Kids Cancer, Ependymoma Research Foundation, St. Baldrick’s Foundation, V Foundation, IronMatt and more.”
Title: Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma
Authors: Andrew Groves, Orville O. Kirkland, Costanza Lo Cascio, Xiuqi Wang, Caleb Heaslip, Joana Graca Marques, Chen Song, Rebecca Poetschke, Tingjian Wang, Diana H. Chin, Yaw Asante, Qi Liu, Hyunmin Kim, Shanqing Gu, Maria Trissal, Jenna Labelle, Gustavo Alencastro Veiga Cruzeiro, Kristen L. Jones, Amy B. Cameron, Louise M. Clark, Brittaney Leeper, Quang-De Nguyen, Berkley E. Gryder, Mariella G. Filbin, Jun Qi
Read the Full Article.
Other articles featuring Susanna Fletcher Greer on OncoDaily.